Effect of N-methyl D-aspartate (NMDA) Receptor Antagonist Dextromethorphan on Opiods Analgesia and Tolerance in Pediatric Intensive Care Unit Patients

Not Applicable

• Conditions: Analgesia Tolerance; Pain; Opioid Tolerance
• Interventions: Drug: Dextromethorphan; Drug: Placebo

• Registration Number: NCT01553435
• Lead Sponsor: King Abdullah International Medical Research Center

Brief Summary

Effect of N-methyl D-aspartate (NMDA) receptor antagonist Dextromethorphan on Opiods analgesia and tolerance in Pediatric Intensive Care Unit Patients

Detailed Description

Not available

Study Timeline

• Study Start: 2011-01
• Study First Submitted: 2012-03-06
• Study First Submitted QC: 2012-03-13
• Study First Posted: 2012-03-14
• Primary Completion: 2015-01
• Status Verified: 2015-04
• Last Update Submitted: 2015-04-12
• Last Update Posted: 2015-04-14

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Not provided

Exclusion Criteria

• Patients under 2 years of age
• Patients with anticipated PICU length of stay less than 3 days.
• Patients shall be excluded if Morphine or Fentanyl infusions not continued for the minimum duration of 72 hours after enrollment
• Patients develops hemodynamic instability
• Patients with Hepatic failure
• Withdrawal request by parent(s)/guardian/family

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Dextromethorphan, opioid analgisia, efficacy	Dextromethorphan	-
Placebo,opioid analgesia, efficacy	Placebo	-

Primary Outcome Measures

Name	Time	Method
Effect of N-methyl D-aspartate (NMDA) receptor antagonist Dextromethorphan on Opiods analgesia and tolerance in Pediatric Intensive Care Unit Patients	Two years	Control of pain

Secondary Outcome Measures

Name	Time	Method
Effect of N-methyl D-aspartate (NMDA) receptor antagonist Dextromethorphan on Opiods analgesia and tolerance in Pediatric Intensive Care Unit Patients	Two years	Length of Hospital Stay in two groups

Trial Locations

Locations (1)

King Abdul Aziz Medical City; 🇸🇦 Riyadh, Central, Saudi Arabia